Developer docs
API playgroundTry for free, no card

Search company profiles

上海药明康德新药开发有限公司

Full company profile

uuid005mefb

Namestring
上海药明康德新药开发有限公司
Legal namestring
无锡药明康德新药开发股份有限公司
Company typeenum
Public
Founded yearint
2000
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
Headquarters浦东, 上海, China
HQ citystring
浦东, 上海
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, pharmaceutical development, drug manufacturing, clinical testing services, oligonucleotide synthesis
Industry3 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Research, Development and Manufacturing (CRDMO) Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1WuXi Chemistry (Chemical Business)
TypeProfessional Services
Description

Provides end-to-end services from chemical drug discovery to commercial manufacturing. Includes small molecule drug discovery (R), process development and manufacturing (D&M), and TIDES (oligonucleotide and peptide) services. 2025 revenue of 364.7 billion RMB with 25.5% YoY growth. Small molecule D&M revenue of 199.2 billion RMB in 2025. TIDES revenue of 113.7 billion RMB with 96% YoY growth.

wuxiapptec.cn
2WuXi Testing
TypeProfessional Services
Description

Comprehensive testing services including drug safety evaluation, DMPK and pre-clinical services. 2025 revenue of 40.4 billion RMB with 4.7% YoY growth. Drug safety evaluation business maintained Asia-Pacific industry leadership.

wuxiapptec.cn
3WuXi Biology
TypeProfessional Services
Description

Biology research and drug discovery services including in-vitro and in-vivo capabilities. 2025 revenue of 26.8 billion RMB with 5.2% YoY growth.

wuxiapptec.cn
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1WuXi Chemistry
Description

Chemical drug discovery, research, and commercial manufacturing services under CRDMO model

wuxiapptec.cn
+4 more records
Core offering1 text field

WuXi AppTec operates an integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform delivering end-to-end pharmaceutical services from drug discovery through commercial manufacturing. Its three core service platforms—WuXi Chemistry (small molecule and TIDES oligonucleotide/peptide discovery, development and manufacturing), WuXi Biology (target discovery, in-vitro/in-vivo pharmacology and candidate screening) and WuXi Testing (drug safety evaluation, DMPK and pre-clinical testing)—serve global pharmaceutical and biotechnology clients across more than 30 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 2025 revenue of 454.6 billion RMB with 15.8% growth; continuing operations 21.4% YoY
+3 more records
Product overview1 text field

WuXi AppTec (药明康德) operates an integrated CRDMO (Contract Research, Development and Manufacturing Organization) business model offering end-to-end pharmaceutical development services. The company provides three core platforms: WuXi Chemistry (chemical drug discovery and manufacturing including TIDES oligonucleotides and peptides), WuXi Biology (comprehensive biology services for drug discovery), and WuXi Testing (drug development testing solutions including safety evaluation and DMPK). The integrated CRDMO platform enables customers to advance molecules from research through development and commercial manufacturing, with operations spanning Asia, Europe and North America.

Product and service7 records
1WuXi Chemistry (化学业务平台)
CategoryPharmaceutical Contract Development and Manufacturing Services
Description

Chemical business platform providing end-to-end CRDMO services from chemical drug discovery research to commercial manufacturing for global pharmaceutical clients, including small molecule and TIDES (oligonucleotides and peptides) services.

2WuXi Biology (生物学业务平台)
CategoryPharmaceutical Contract Research Services
Description

Comprehensive biology services and solutions supporting target discovery through candidate drug screening and clinical development, including in vitro and in vivo pharmacology capabilities for pharmaceutical and biotechnology clients.

3WuXi Testing (测试业务平台)
CategoryPharmaceutical Contract Testing Services
Description

Testing business platform providing full lifecycle integrated drug development testing solutions, including drug safety evaluation and DMPK services, maintaining global high-quality standards for pharmaceutical clients.

4TIDES (Oligonucleotides and Peptides)
CategoryPharmaceutical Contract Manufacturing Services
Description

Oligonucleotides and peptides development and manufacturing services for emerging therapeutic modalities under WuXi Chemistry, with multi-pillar synthesis reactor capacity exceeding 100,000L and 2025 TIDES business revenue of 113.7 billion RMB (96% YoY growth).

5WuXi STA (合全药业)
CategoryPharmaceutical Contract Manufacturing Services
Description

Small molecule R&D and manufacturing subsidiary providing pharmaceutical drug substance and drug product manufacturing services, including API manufacturing operations across U.S. sites in Middletown, Delaware and San Diego, California.

6WuXi DMPK
CategoryPharmaceutical Contract Testing Services
Description

Drug metabolism and pharmacokinetics (DMPK) and pre-clinical services operated from the Cranbury, New Jersey facility, supporting pharmaceutical and biotech clients with pre-clinical pharmacology testing.

7LabNetwork (览博网) Compound Library Service Platform
CategoryDrug Discovery Services Platform
Description

Compound library service platform providing researchers with compound library design, search, ordering and screening services, offering access to WuXi AppTec's novel screening compound libraries and one-stop biology screening services for drug discovery researchers.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1NEOM (Saudi Arabia)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-10-28
Description

WuXi AppTec signed strategic cooperation memorandums with NEOM (New Future City project in Saudi Arabia) and Saudi Ministry of Health to expand CRDMO platform services locally. NEOM is a sustainable development city under construction in northwestern Saudi Arabia.

wuxiapptec.cn
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-10-28
Description

Strategic cooperation memorandum signed with Saudi Ministry of Health to explore expanding CRDMO platform services in Saudi Arabia, supporting the country's healthcare and pharmaceutical development objectives.

Strategic tierCoreTypeOthers
Description

WuXi AppTec has joined the UN Global Compact, committing to support the ten principles of the UNGC and integrating sustainable business practices into company operations.

Strategic tierCoreTypeOthers
Description

As a PSCI supplier partner, WuXi AppTec participates in the pharmaceutical supply chain initiative promoting responsible supply chain practices in the pharmaceutical industry.

Strategic tierCoreTypeOthers
Description

WuXi AppTec's near-term greenhouse gas emission reduction targets have been validated and approved by SBTi, demonstrating commitment to science-based climate action.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Korean CDMO specializing in biologics contract manufacturing with large-scale mammalian capacity. Comparable to WuXi's biologics-adjacent CDMO scale and global pharma client base.

TypeDirect peer
Description

US CRO/CDMO providing discovery, safety assessment and manufacturing services to pharma/biotech. Directly comparable to WuXi's Biology and Testing (DSE) platforms and competes for outsourced preclinical work.

3Recipharm
TypeRegional player
Description

European CDMO offering pharmaceutical formulation, API and drug product manufacturing services, now part of the Recipharm/Dr. Reddy's ecosystem. Comparable CDMO business model to WuXi, focused on the European pharma customer base.

TypeBroad incumbent
Description

Global CRO and clinical/research services giant serving pharma across R&D, clinical trials and real-world evidence. Broader incumbent that overlaps WuXi's clinical/biology/testing services but at much larger scale and different mix.

TypeEmerging player
Description

US-based clinical and commercial CRO with end-to-end pharma services. Comparable to WuXi's clinical services offering prior to the 2025 China Clinical Research Services divestiture.

TypeDirect peer
Description

Swiss-headquartered global CDMO leader offering API, biologics and integrated drug substance/product manufacturing. Closely comparable to WuXi AppTec in integrated small molecule and oligonucleotide/peptide CDMO services to global pharma.

TypeBroad incumbent
Description

Ireland-headquartered global CRO providing clinical research services to pharma/biotech. Comparable to the clinical research portion of WuXi's former China Clinical Research Services business (now divested).

TypeEmerging player
Description

Hong Kong-listed biologics CDMO with global manufacturing footprint, spun out of the broader WuXi ecosystem. Closely comparable in CRDMO model and biologics manufacturing, though focused on biologics rather than WuXi AppTec's broader small molecule/TIDES mix.

TypeBroad incumbent
Description

Diversified life sciences tools and CDMO operator (via Patheon) offering drug substance/product manufacturing and clinical supply services. Broad incumbent competing with WuXi for integrated small molecule and biologics CDMO work.

TypeDirect peer
Description

Major US-headquartered CDMO providing drug substance, drug product and biologics development/manufacturing, recently taken private by Novo Holdings. Directly comparable to WuXi in commercial-stage small molecule and biologics CDMO offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

上海药明康德新药开发有限公司

Pharmaceutical Contract Research, Development and Manufacturing (CRDMO) Serviceswuxiapptec.com.cn

上海药明康德新药开发有限公司 firmographics

Firmographics
Name
上海药明康德新药开发有限公司
Legal name
无锡药明康德新药开发股份有限公司
Website
https://wuxiapptec.com.cn
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

上海药明康德新药开发有限公司 industry classification

Industry
Product category
Pharmaceutical Contract Research, Development and Manufacturing (CRDMO) Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Contract research services
  • Pharmaceutical development
  • Drug manufacturing
  • Clinical testing services
  • Oligonucleotide synthesis

Where 上海药明康德新药开发有限公司 is headquartered

Location

Headquarters

HQ city
浦东, 上海
HQ country
China
HQ region
Asia

Offices9 records

Markets served

上海药明康德新药开发有限公司 business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. WuXi Chemistry (Chemical Business): Provides end-to-end services from chemical drug discovery to commercial manufacturing. Includes small molecule drug discovery (R), process development and manufacturing (D&M), and TIDES (oligonucleotide and peptide) services. 2025 revenue of 364.7 billion RMB with 25.5% YoY growth. Small molecule D&M revenue of 199.2 billion RMB in 2025. TIDES revenue of 113.7 billion RMB with 96% YoY growth.
  2. WuXi Testing: Comprehensive testing services including drug safety evaluation, DMPK and pre-clinical services. 2025 revenue of 40.4 billion RMB with 4.7% YoY growth. Drug safety evaluation business maintained Asia-Pacific industry leadership.
  3. WuXi Biology: Biology research and drug discovery services including in-vitro and in-vivo capabilities. 2025 revenue of 26.8 billion RMB with 5.2% YoY growth.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

上海药明康德新药开发有限公司 product offering

Product offering

Core offering

WuXi AppTec operates an integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform delivering end-to-end pharmaceutical services from drug discovery through commercial manufacturing. Its three core service platforms—WuXi Chemistry (small molecule and TIDES oligonucleotide/peptide discovery, development and manufacturing), WuXi Biology (target discovery, in-vitro/in-vivo pharmacology and candidate screening) and WuXi Testing (drug safety evaluation, DMPK and pre-clinical testing)—serve global pharmaceutical and biotechnology clients across more than 30 countries.

Product overview

WuXi AppTec (药明康德) operates an integrated CRDMO (Contract Research, Development and Manufacturing Organization) business model offering end-to-end pharmaceutical development services. The company provides three core platforms: WuXi Chemistry (chemical drug discovery and manufacturing including TIDES oligonucleotides and peptides), WuXi Biology (comprehensive biology services for drug discovery), and WuXi Testing (drug development testing solutions including safety evaluation and DMPK). The integrated CRDMO platform enables customers to advance molecules from research through development and commercial manufacturing, with operations spanning Asia, Europe and North America.

Differentiator

Problem solved

Functional benefit

Brands

  • WuXi Chemistry: Chemical drug discovery, research, and commercial manufacturing services under CRDMO model
  • WuXi Biology
  • WuXi Testing
  • TIDES
  • WuXi STA (合全药业)

Products and services

  • WuXi Chemistry (化学业务平台) Chemical business platform providing end-to-end CRDMO services from chemical drug discovery research to commercial manufacturing for global pharmaceutical clients, including small molecule and TIDES (oligonucleotides and peptides) services.
  • WuXi Biology (生物学业务平台) Comprehensive biology services and solutions supporting target discovery through candidate drug screening and clinical development, including in vitro and in vivo pharmacology capabilities for pharmaceutical and biotechnology clients.
  • WuXi Testing (测试业务平台) Testing business platform providing full lifecycle integrated drug development testing solutions, including drug safety evaluation and DMPK services, maintaining global high-quality standards for pharmaceutical clients.
  • TIDES (Oligonucleotides and Peptides) Oligonucleotides and peptides development and manufacturing services for emerging therapeutic modalities under WuXi Chemistry, with multi-pillar synthesis reactor capacity exceeding 100,000L and 2025 TIDES business revenue of 113.7 billion RMB (96% YoY growth).
  • WuXi STA (合全药业) Small molecule R&D and manufacturing subsidiary providing pharmaceutical drug substance and drug product manufacturing services, including API manufacturing operations across U.S. sites in Middletown, Delaware and San Diego, California.
  • WuXi DMPK Drug metabolism and pharmacokinetics (DMPK) and pre-clinical services operated from the Cranbury, New Jersey facility, supporting pharmaceutical and biotech clients with pre-clinical pharmacology testing.
  • LabNetwork (览博网) Compound Library Service Platform Compound library service platform providing researchers with compound library design, search, ordering and screening services, offering access to WuXi AppTec's novel screening compound libraries and one-stop biology screening services for drug discovery researchers.

Quantifiable outcome

  • 2025 revenue of 454.6 billion RMB with 15.8% growth; continuing operations 21.4% YoY
  • +3 more outcomes

Companies that use 上海药明康德新药开发有限公司

Customer profile

Segments2 records

Ideal customer profiles2 records

上海药明康德新药开发有限公司 technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

上海药明康德新药开发有限公司 partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered strategic and core.

  • NEOM (Saudi Arabia)strategicStrategic or Co-development Partner · 28 October 2025WuXi AppTec signed strategic cooperation memorandums with NEOM (New Future City project in Saudi Arabia) and Saudi Ministry of Health to expand CRDMO platform services locally. NEOM is a sustainable development city under construction in northwestern Saudi Arabia.
  • Saudi Ministry of HealthstrategicStrategic or Co-development Partner · 28 October 2025Strategic cooperation memorandum signed with Saudi Ministry of Health to explore expanding CRDMO platform services in Saudi Arabia, supporting the country's healthcare and pharmaceutical development objectives.
  • United Nations Global Compact (UNGC)coreOthersWuXi AppTec has joined the UN Global Compact, committing to support the ten principles of the UNGC and integrating sustainable business practices into company operations.
  • Pharmaceutical Supply Chain Initiative (PSCI)coreOthersAs a PSCI supplier partner, WuXi AppTec participates in the pharmaceutical supply chain initiative promoting responsible supply chain practices in the pharmaceutical industry.
  • Science Based Targets initiative (SBTi)coreOthersWuXi AppTec's near-term greenhouse gas emission reduction targets have been validated and approved by SBTi, demonstrating commitment to science-based climate action.

Scale indicators13 records

Recent moves9 records

Expansion highlights4 records

上海药明康德新药开发有限公司 competitors and assessment

Company assessment

Direct peers

  • Samsung Biologics: Korean CDMO specializing in biologics contract manufacturing with large-scale mammalian capacity. Comparable to WuXi's biologics-adjacent CDMO scale and global pharma client base.
  • Charles River Laboratories: US CRO/CDMO providing discovery, safety assessment and manufacturing services to pharma/biotech. Directly comparable to WuXi's Biology and Testing (DSE) platforms and competes for outsourced preclinical work.
  • Lonza Group: Swiss-headquartered global CDMO leader offering API, biologics and integrated drug substance/product manufacturing. Closely comparable to WuXi AppTec in integrated small molecule and oligonucleotide/peptide CDMO services to global pharma.
  • Catalent (Novo Holdings): Major US-headquartered CDMO providing drug substance, drug product and biologics development/manufacturing, recently taken private by Novo Holdings. Directly comparable to WuXi in commercial-stage small molecule and biologics CDMO offerings.

Regional players

  • Recipharm: European CDMO offering pharmaceutical formulation, API and drug product manufacturing services, now part of the Recipharm/Dr. Reddy's ecosystem. Comparable CDMO business model to WuXi, focused on the European pharma customer base.

Broad incumbents

  • IQVIA: Global CRO and clinical/research services giant serving pharma across R&D, clinical trials and real-world evidence. Broader incumbent that overlaps WuXi's clinical/biology/testing services but at much larger scale and different mix.
  • ICON plc: Ireland-headquartered global CRO providing clinical research services to pharma/biotech. Comparable to the clinical research portion of WuXi's former China Clinical Research Services business (now divested).
  • Thermo Fisher Scientific (Patheon CDMO): Diversified life sciences tools and CDMO operator (via Patheon) offering drug substance/product manufacturing and clinical supply services. Broad incumbent competing with WuXi for integrated small molecule and biologics CDMO work.

Emerging players

  • Syneos Health: US-based clinical and commercial CRO with end-to-end pharma services. Comparable to WuXi's clinical services offering prior to the 2025 China Clinical Research Services divestiture.
  • WuXi Biologics: Hong Kong-listed biologics CDMO with global manufacturing footprint, spun out of the broader WuXi ecosystem. Closely comparable in CRDMO model and biologics manufacturing, though focused on biologics rather than WuXi AppTec's broader small molecule/TIDES mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

上海药明康德新药开发有限公司 social profiles

Digital presence

上海药明康德新药开发有限公司 compliance and trust

Trust signal

Compliance4 records

上海药明康德新药开发有限公司 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

上海药明康德新药开发有限公司 leadership team

Management profile

Number of profiles

Profiles3 records

上海药明康德新药开发有限公司 subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

上海药明康德新药开发有限公司 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

上海药明康德新药开发有限公司 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 上海药明康德新药开发有限公司

What does 上海药明康德新药开发有限公司 do?

WuXi AppTec operates an integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform delivering end-to-end pharmaceutical services from drug discovery through commercial manufacturing. Its three core service platforms—WuXi Chemistry (small molecule and TIDES oligonucleotide/peptide discovery, development and manufacturing), WuXi Biology (target discovery, in-vitro/in-vivo pharmacology and candidate screening) and WuXi Testing (drug safety evaluation, DMPK and pre-clinical testing)—serve global pharmaceutical and biotechnology clients across more than 30 countries.

Is 上海药明康德新药开发有限公司 a public or private company?

上海药明康德新药开发有限公司 is a public company. It is classified as public and is currently operating.

When was 上海药明康德新药开发有限公司 founded?

上海药明康德新药开发有限公司 was founded in 2000. It employs 501 to 1,000 people.

Where is 上海药明康德新药开发有限公司 based?

上海药明康德新药开发有限公司 is headquartered in 浦东, 上海, China, in the Asia region.

How does 上海药明康德新药开发有限公司 make money?

Three revenue lines are on record. WuXi Chemistry (Chemical Business) is the primary driver. The others are wuXi Testing and wuXi Biology.

Who are 上海药明康德新药开发有限公司's main competitors?

Direct peers on record are Samsung Biologics, Charles River Laboratories, Lonza Group and Catalent (Novo Holdings). Recipharm is listed as a regional player. Broad incumbents are IQVIA, ICON plc and Thermo Fisher Scientific (Patheon CDMO). Emerging players are Syneos Health and WuXi Biologics.

Does 上海药明康德新药开发有限公司 have an API?

No public API is recorded for 上海药明康德新药开发有限公司.

What industry is 上海药明康德新药开发有限公司 in?

上海药明康德新药开发有限公司's product category is Pharmaceutical Contract Research, Development and Manufacturing (CRDMO) Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales